Chronic hepatitis B is persistent hepatitis B, which means the hepatitis B virus persists in the body for more than 6 months. Unlike most pa
Chronic hepatitis B is persistent hepatitis B, which means the hepatitis B virus persists in the body for more than 6 months. Unlike most patients with acute hepatitis B, chronic hepatitis B has no symptoms. About 1/3 of patients in the presence of hepatitis symptoms, mainly manifested as fatigue and insomnia, and most patients can tolerate, work, study and life. Symptoms disappeared after hepatitis.
Because of the lack of symptoms in patients with chronic hepatitis B during the inactive period and the presence of tolerable symptoms during the active period, very few patients have been diagnosed with active treatment. In general, the discovery of chronic hepatitis B relies mainly on passive physical examination. Early detection of chronic hepatitis B strategy should be, when there are symptoms of fatigue and insomnia, the initiative to carry out the relevant checks.
Although only a small number of patients with chronic hepatitis B can be cured or cured in their lifetime. The most common adverse outcome of chronic hepatitis B with a lack of significant and specific symptoms was cirrhosis, followed by hepatocellular carcinoma. Liver cirrhosis and hepatocellular carcinoma are the main reasons why patients seek medical help, but the current level of medical development is still far from the problem of cirrhosis and hepatocellular carcinoma.
Liver cirrhosis is a kind of pathological state of liver decompensation. Liver decompensation refers to the disease state can not maintain normal life activities, can be manifested as persistent jaundice, skin edema, ascites and ascites infection, upper gastrointestinal bleeding, disturbance of consciousness, mental disorders, memory loss, loss calculation.
Hepatocellular carcinoma is a variant of hepatocyte proliferation. The proliferation of liver cancer cells need to consume a large amount of nutrients, the human body needs to consume a lot of liver cancer cells. Therefore, the performance of advanced hepatocellular carcinoma often have weight loss, at the same time, all or part of the liver decompensation, but also pain and metastasis of liver cancer cells.
The main purpose of the treatment of chronic hepatitis B is to reduce the frequency of hepatitis and prevent the occurrence of liver cirrhosis and hepatocellular carcinoma. The main measures for the treatment of chronic hepatitis B includes a balanced diet, avoid excessive fatigue, jaundice, liver, immune regulation, antiviral. A balanced diet requires a variety of food should be diversified, can follow the feeling of eating desire to go, but not excessive. Including physical and mental fatigue stress fatigue, avoid excessive overworked is not equal to rest in bed, can maintain appropriate activities or work, but to do "".
The drug in the treatment of chronic hepatitis B, not by the merits of "disease differentiation" to solve the problem of individual patients. Therefore, the treatment of chronic hepatitis B drug selection principle should be based on the characteristics of the patient's condition to make a reasonable choice, according to the patient's condition to adjust.
There is evidence that serum e antigen of hepatitis B conversion can reduce the frequency of cirrhosis and hepatocellular carcinoma, hepatitis B surface antigen seroconversion can cause liver disease basically stopped; reduce the serum virus content, not only can reduce the frequency of cirrhosis and hepatocellular carcinoma, and can delay the progression and reversal of liver disease.
Interferon alpha can promote the seroconversion of hepatitis B e antigen and surface antigen, which can only make the e antigen seroconversion in some patients. Nucleoside (acid) antiviral drugs can reduce the content of serum virus, but do not promote hepatitis B e antigen and surface antigen seroconversion. Interferon alpha has the advantage of limited treatment, but the curative effect is not high; nucleoside (acid) antiviral drugs have high curative effect, but the course of treatment is uncertain.
Therefore, the path to a reasonable choice for the treatment of chronic hepatitis B should be the first choice for interferon alpha therapy in patients who are likely to be effective. For patients with interferon alpha therapy ineffective or interferon alpha therapy may be ineffective, the first choice of nucleoside (acid) antiviral drugs. Thymosin, vaccine may contribute to the increase of interferon or nucleoside (acid) the efficacy of antiviral drugs. For a small number of immune regulation and antiviral were ineffective with use of hepatoprotective drugs.